WOK WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through with its subsidiaries, manufactures and sells medical consumables and devices in the People's Republic of China and internationally. The company offers medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, yankauer suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half masks; visualized prostatic dilatation catheters; and nebulizer kits, SPO2 sensors, nasogastric tubes, personal protective equipment, hygiene and skincare products, cleaners for household use, and non-powered air-purifying particle respirators. It also engages in the research and development of biological and medical technology; and sale of chemical products. The company serves hospitals, pharmacies, and medical institutions. It exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD has strategic cooperation agreement with Shanghai Novabioplus Biotechnology Co., Ltd. to develop data-model-application trinity for intelligent medical models. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.…
Industry Peers
Medical DevicesKey Statistics
About WORK Medical Technology Group (NASDAQ: WOK)
›
WORK Medical Technology Group (NASDAQ: WOK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 238 employees.
The shares were at 1.155 USD on 19 November 2026, down 100.0% over 52 weeks. Its 52-week range is 0.9117 USD to 83600.00 USD: the price is 100.0% below the high and 26.7% above the low.
Its market capitalisation is 5.16M USD.
WORK Medical Technology Group reports return on equity of -5.8%, an operating margin of -41.7% and revenue up 19.1% year over year.
Its debt exceeds its cash by 3.37M USD, a debt-to-equity ratio of 0.35. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.